Quest Diagnostics LLC Il

Quest Diagnostics LLC Il was paid $6.55M by Medicaid between Jan 2018 and Oct 2024, across 150 billing codes. Its largest line is G0480, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed — 10% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Minnesota

Rank by total paid#10 of 69

Median peer was paid$48K

This provider vs. median136×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	48,112	$290K
2019	53,484	$1.22M
2020	49,620	$1.08M
2021	77,796	$1.76M
2022	41,406	$880K
2023	42,687	$793K
2024incomplete	28,949	$536K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	10%	9,167	5,229	$680K
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	10%	8,792	8,290	$677K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	6.9%	14,963	14,312	$450K
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	6.8%	14,826	14,193	$445K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	6.6%	12,241	6,513	$435K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	4.1%	10,585	10,279	$270K
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	3.1%	9,569	9,355	$201K
80050	General health panel	3.0%	4,574	4,450	$196K
84443	Thyroid stimulating hormone (TSH)	2.5%	11,557	11,278	$165K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	2.2%	6,046	5,685	$145K
80061	Lipid panel	2.1%	12,011	11,673	$138K
86003		2.0%	1,532	1,455	$133K

138 more codes

86480		1.9%	2,267	$124K
80053	Comprehensive metabolic panel	1.6%	11,522	$104K
87624	Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types	1.5%	3,346	$102K
88175	Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer	1.4%	4,152	$95K
83013		1.4%	1,684	$93K
83036	Hemoglobin; glycosylated (A1C)	1.3%	9,976	$85K
86803		1.3%	6,861	$85K
84403		1.3%	3,575	$84K
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	1.2%	2,473	$79K
82670		1.1%	2,869	$73K
82728		1.1%	6,026	$73K
83655		1.0%	3,170	$66K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	1.0%	9,788	$66K
84481		1.0%	4,362	$66K
80081		<1%	1,079	$65K
82607		<1%	4,734	$62K
87086	Culture, bacterial; quantitative colony count, urine	<1%	7,771	$53K
86592		<1%	14,355	$53K
36415	Collection of venous blood by venipuncture	<1%	12,560	$47K
84439		<1%	5,703	$45K
81513		<1%	339	$45K
87801	Infectious agent detection by nucleic acid; amplified probe, multiple organisms	<1%	644	$44K
87088		<1%	6,048	$43K
84144		<1%	1,982	$37K
87799		<1%	283	$34K
87340		<1%	3,518	$31K
83550		<1%	3,904	$30K
84402		<1%	1,232	$30K
80048	Basic metabolic panel (calcium, ionized)	<1%	4,192	$30K
84702		<1%	2,418	$29K
83001		<1%	1,779	$29K
86376		<1%	2,198	$28K
82746		<1%	2,114	$27K
85027		<1%	4,624	$27K
82627		<1%	1,260	$26K
86800		<1%	1,767	$25K
83540		<1%	4,006	$23K
87186		<1%	2,680	$20K
87081		<1%	3,672	$20K
86706		<1%	2,018	$18K
84146		<1%	1,129	$18K
87070		<1%	2,483	$18K
87510		<1%	1,060	$18K
87480		<1%	1,061	$18K
87660		<1%	1,061	$17K
82533		<1%	1,054	$17K
88142		<1%	1,038	$17K
88305	Level IV - Surgical pathology, gross and microscopic examination	<1%	255	$16K
86038		<1%	1,536	$15K
86704		<1%	1,500	$15K
87077		<1%	2,139	$15K
83002		<1%	916	$15K
84460		<1%	2,923	$13K
80076		<1%	1,912	$13K
82570		<1%	2,746	$13K
87636	Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B	<1%	85	$12K
84450		<1%	2,670	$12K
86140		<1%	2,546	$12K
86769		<1%	238	$12K
86787		<1%	1,061	$11K
86708		<1%	964	$11K
87512		<1%	257	$11K
87522	Neg quan hep c or qual rna	<1%	250	$11K
83520		<1%	525	$10K
83970		<1%	255	$10K
82043		<1%	1,794	$9K
86780		<1%	649	$8K
87147		<1%	1,628	$8K
81001		<1%	2,332	$7K
82784		<1%	602	$7K
83735		<1%	1,090	$6K
82950		<1%	1,182	$5K
82785		<1%	345	$5K
84153		<1%	296	$5K
85018		<1%	2,160	$5K
84270		<1%	211	$4K
80074		<1%	132	$4K
84681		<1%	209	$4K
82565		<1%	990	$4K
88141		<1%	181	$4K
85652		<1%	1,736	$4K
84550		<1%	943	$4K
81025		<1%	425	$3K
83014		<1%	566	$3K
87255		<1%	151	$3K
80069		<1%	380	$3K
83516		<1%	232	$3K
82397		<1%	237	$3K
84156		<1%	825	$3K
84480		<1%	856	$2K
82652		<1%	58	$2K
87210		<1%	395	$2K
87637	Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV	<1%	14	$2K
81003		<1%	1,003	$2K
86431		<1%	374	$2K
86364		<1%	278	$2K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	35	$2K
82947		<1%	490	$2K
84436		<1%	240	$1K
86696		<1%	107	$1K
86762		<1%	103	$1K
87338		<1%	96	$1K
82465		<1%	377	$1K
87517		<1%	26	$1K
82040		<1%	184	$858.62
87536		<1%	12	$851.00
86617		<1%	26	$813.04
83690		<1%	131	$782.12
87880	Infectious agent antigen detection by immunoassay; Streptococcus, group A	<1%	46	$745.05
86001		<1%	60	$696.96
83718		<1%	113	$675.24
86618		<1%	67	$644.81
84478		<1%	132	$607.84
82248		<1%	217	$570.84
84479		<1%	77	$482.82
85660		<1%	93	$457.33
84482		<1%	54	$425.52
86317		<1%	34	$407.37
82951		<1%	30	$373.23
83525		<1%	41	$368.88
82542		<1%	14	$314.46
86900		<1%	99	$294.45
86850		<1%	30	$263.79
86901		<1%	87	$258.57
82105		<1%	13	$242.32
86765		<1%	25	$186.03
86735		<1%	12	$174.00
82550		<1%	31	$158.95
86705		<1%	15	$141.24
84630		<1%	12	$136.89
85610		<1%	30	$128.70
84100		<1%	26	$118.59
82952		<1%	30	$113.68
83721		<1%	38	$84.00
82150		<1%	12	$77.76
84132		<1%	13	$63.69
86593		<1%	12	$52.80
82310		<1%	12	$51.60

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialCARTIER, GERALD (VP OF REVENUE SERVICES)

Parent organizationQUEST DIAGNOSTICS INCORPORATED

Same official

Other billing entities under CARTIER, GERALD

Full network →

Provider	Location	Paid
Metwest INC.	Billings, MT	$69K
Unilab Corporation	Banning, CA	$37K
Metwest INC.	West Valley City, UT	$11K
Quest Diagnostics Clinical Laboratories INC	Rocky Mount, NC	$7K

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.